Zelinska, N.,
Iotova, V.,
Skorodok, J.,
Malievsky, O.,
Peterkova, V.,
Samsonova, L.,
Rosenfeld, Ron G.,
Zadik, Zvi,
Jaron-Mendelson, Michal,
Koren, Ronit,
Amitzi, Leanne,
Raduk, Dmitri,
Hershkovitz, Oren,
Hart, Gili (2017) -binding peptide 3 showed a
dose-
dependent increase during MOD-4023 treatment. IGF-I standard deviation score
KORYTINA, G.F.,
AKHMADISHINA, L.Z.,
KOCHETOVA, O.V.,
VIKTOROVA, T.V.,
AZNABAEVA, Y.G.,
ZAGIDULLIN, N.SH.,
ZAGIDULLIN, SH.Z.,
KZHYSHKOWSKA, J.G (2019) .005, P=0.0028, P=0.015). A significant genotype-
dependent variation of forced vital capacity and forced
Zagidullin, N.,
Plechev, V.,
Badykova, E.,
Badykov, M.,
Akhmadishina, L.,
Korytina, G.,
Sagitov, I. (2019) in the control group (36.2%) compared with SSS patients (28.9%) Padj=0.052. Analysis,
depending on the type
Bogliolo, M.,
Catucci, I.,
Caleca, L.,
Lasheras, S.V.,
Pujol, R.,
Kiiski, J.I.,
Muranen, T.A.,
Barnes, D.R.,
Dennis, J.,
Michailidou, K.,
Bolla, M.K.,
Leslie, G.,
Figlioli, G. (2019) variants on breast cancer risk may
depend on their position in the gene. Cell sensitivity to olaparib
Korytina, G.F.,
Akhmadishina, L.Z.,
Kochetova, O.V.,
Aznabaeva, Y.G.,
Zagidullin, Sh.Z.,
Victorova, T.V. (2016) .045, P = 0.004, P = 0.0005, P = 0.021, and P = 0.042). A significant genotype-
dependent variation
Onorato, EM,
Alamanni, F,
Muratori, M,
Smolka, G,
Wojakowski, W,
Pysz, P,
Zorinas, A,
Zakarkaite, D,
Eltchaninoff, H,
Litzer, PY,
Godart, F,
Calvert, P,
Christou, C,
Mussayev, A,
Missiroli, B,
Buzaev, I,
Curello, S,
Tesorio, T,
Bartorelli, AL (2022) parameters, including NYHA class and a reduced
dependency on hemolysis-related blood transfusions.